The Top Biotech Stocks to Watch Following ASH 2019

The annual American Society of Hematology (ASH) conference has historically been fertile ground for revolutionary advances in the treatment of blood disorders and cancers. This year was no exception. Among the thousands of presentations at the conference, a number of groundbreaking advances were reported, including impressive results in multiple myeloma, beta thalassemia, acute myeloid leukemia,…

3 Biotech Stocks That Crushed It in 2019

Here’s why these drugmaker stocks are the year’s top performers. This has been a great year for the overall stock market and a banner year for a handful of drugmakers that don’t even have a product to sell yet.  These three biotech stocks entered 2019 ready to provide market-thumping returns, and they delivered. Let’s look…

A scientist who genetically edited babies was just sentenced to 3 years in prison. Here’s how he did it and why scientists around the world are outraged.

A Chinese court on Monday sentenced He Jiankui, the scientist who claimed in 2018 that the first two gene-edited babies had been born, to three years in prison, according to Chinese state media reports.The court sentenced two of He’s colleagues to time in prison as well, concluding that the three violated Chinese regulations, practiced medicine…

Why Aptose Biosciences Shares Are Jumping Today

Investors excited about the biotech’s prospects are taking the opportunity to buy on the dip following the announcement of a new stock offering. What happened Shares of Aptose Biosciences (NASDAQ:APTO) were jumping 14% higher as of 3:14 p.m. EST on Wednesday. The clinical-stage biotech announced on Tuesday that its public stock offering of more than…

3 Stocks That Could Be the Next Biotech Buyouts

Here are the biotechs most likely to receive juicy buyout offers in 2020. When asked recently about which biopharmaceutical companies will be the most likely takeout targets in 2020, analysts at J.P. Morgan were most enthusiastic about Uniqure (NASDAQ:QURE), Amarin (NASDAQ:AMRN), and Acadia Pharmaceuticals (NASDAQ:ACAD).  What do these three biopharmaceutical companies have that makes them attractive to deep-pocketed pharmaceutical…

Biotech’s Most Volatile Binary Events for Q1

Risk-taking investors flock to biotech for its constant flow of events that can spike or crush the stock prices of the companies developing the latest therapies. Nothing provides greater stock price swings in the biotech sector than late-stage clinical trial results and drug approval decisions from the U.S. Food and Drug Administration. A recent research…

4 Healthcare Services Companies to Own for the Future

Many investors aren’t aware of the vital roles contract research organizations fulfill for pharmaceutical and biotech companies — or of the billions they make each year for their services. The U.S. Food and Drug Administration has approved more than 145 new drugs since the start of 2017, and a few more could join their ranks…

3 Reasons This Biotech is a Buy for Risk-Averse Investors

Biotech can be a risky sector for those interested in healthcare stocks, but Amgen has found a way to manage the risk and reap the rewards. Because they are always dealing with complicated regulations, patents, recalls, and fierce competition, biotech stocks can feel like risky investments. Many biotechs try to tackle some of the world’s…

3 Biotech Stocks That Can Double Your Money in 2020

If you want to see your investment in the biotech market grow two-fold, these are the top stocks to buy. While the world of biotech has always been an interesting one, now’s an especially exciting time to consider investing in the sector. There are many potential blockbuster drugs awaiting U.S. Food and Drug Administration (FDA)…